91 filings
Page 5 of 5
6-K
uxzmce1whc3o oi
28 Apr 20
I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202
6:14am
6-K
t0uhs1 smv4lpwk
17 Apr 20
Current report (foreign)
4:01pm
6-K
os4xxaz2c 7f
8 Apr 20
Current report (foreign)
6:29am
6-K
pdm6if3c48k
6 Apr 20
Current report (foreign)
4:06pm
6-K
zru5v3cggq3u3cof
2 Apr 20
Initiation of development of TJC4 in China follows an ongoing Phase 1 study in U.S. for advanced solid tumors and lymphoma
4:03pm
6-K
svax6udne7d syc06pp
31 Mar 20
Successfully completed initial public offering raising approximately $114.5 million in gross proceeds
7:51am
6-K
cdvx1ivpiur9u0a3ga8
30 Mar 20
I-Mab Enters into Strategic Regional Partnership with Kalbe Genexine Biologics
4:02pm
6-K
7xoilyds4m4gocdn0x
27 Mar 20
I-Mab Expands GlobalOut-Licensing and Business Development Efforts
8:39am
6-K
ijdk896a594 gdhub4p
23 Mar 20
I-Mab Appoints Gigi Feng as Vice President and Global Head of Corporate Communications
6:18am
6-K
5s6ve12dahvxa
13 Mar 20
I-Mab Biopharma Announces Development of TJM2 to Treat Cytokine Release
4:03pm
6-K
6vcgio 77uu
10 Feb 20
I-Mab Announces Partial Exercise of Over-Allotment Option in Initial Public Offering
4:03pm